As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Corporate Overview

December 16, 2020 – Cambridge Isotope Laboratories, Inc. Announces 13C Cascade Production Optimization at Ohio Plant

Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), recently began a significant capacity optimization of one of the production cascades at the 13C separation facility in Xenia, Ohio. This optimization, which began this past summer and is scheduled for completion in the summer of 2021, will increase the cascade’s 13C production by 10%. This follows the most recent expansion completion earlier this year, which increased 13C production capacity by 25%.

September 22, 2020 – Eurisotop Responds to Market Demand for Deuterated Chloroform

Eurisotop, a wholly owned subsidiary of Cambridge Isotope Laboratories, Inc. (CIL), announced a capacity expansion of its deuterated chloroform production. Since its acquisition by CIL in 2001, Eurisotop has become a leading producer of deuterated NMR solvents and is the premier supplier of CIL stable isotope-labeled compounds in Europe. Eurisotop initially operated one reactor that produced 6 tons of deuterated chloroform per year. This new expansion consisted of adding a second reactor (twin reactors) and when operating simultaneously and continuously can produce tens of tons of product per year.

September 2, 2020 – Cambridge Isotope Laboratories, Inc. Expands Benzene and Bromobenzene Capacities to Meet Customer Demands

Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotopes and stable isotope-labeled compounds, recently announced a capacity expansion for deuterated benzene at Cambridge Isotope Separations, LLC (CIS), located on 33 acres in Xenia, Ohio. This capacity expansion started in the summer of 2019 and consisted of two new reactors being added; the first was active in January 2020 and the second new reactor came online this summer. To complete the final phase of this expansion, an additional distillation unit will be active by the end of 2020. This is the first deuterated benzene capacity expansion at CIS since the process began in 2008.

August 12, 2020 – Cambridge Isotope Laboratories, Inc. Announces Expansion of 13C Capacity at Ohio Plant

Cambridge Isotope Laboratories, Inc. (CIL), the world leader in stable isotope chemistry and the separation of carbon-13 (13C), recently completed a significant expansion of its 13C separation facility. In 1987, CIL took the initiative to construct the world’s largest 13C isotope-separation plant, Cambridge Isotope Separations, LLC (CIS), located on 33 acres in Xenia, Ohio.13C is a critical starting material supporting development of new research and diagnostic chemicals. Following expansions in 1996, 2012, and 2015, CIL embarked on a new expansion in 2018 which was completed earlier this year. This most recent expansion increased production capacity of 13C by 25%.

July 29, 2020 – Cambridge Isotope Laboratories Appoints Todd Osiek, PhD as Chief Science Officer

Cambridge Isotope Laboratories, Inc., the leading manufacturer of stable isotope and stable isotope-labeled compounds worldwide, is pleased to announce the addition of Todd Osiek, PhD, as Chief Science Officer (CSO). Osiek reports directly to the CEO, Cliff Caldwell. As CSO, Osiek is responsible for supporting operations development of best practices in safety and quality, working with sales and marketing on new-product development, and mapping out strategic directions and opportunities.

July 15, 2020 – Cambridge Isotope Laboratories Appoints Warren Arenz as Vice President of Operations

Cambridge Isotope Laboratories, Inc, the world’s leading manufacturer of stable isotopes and stable isotope-labeled compounds, is pleased to announce the addition of Warren Arenz as Vice President of Operations. Arenz reports directly to the CEO, Cliff Caldwell.

July 2, 2020 – In the Wake of COVID-19, CIL Holds Local Food Drive

CIL recognizes the high level of food insecurities due to COVID-19 and wanted to give to the surrounding communities in need.To help those facing food insecurity in the wake of the COVID-19 outbreak, CIL held a food and personal care item drive supporting the Lawrence YMCA Food Pantry, partner of the Merrimack Valley Food Bank, Inc.

June 10, 2020 – Cambridge Isotope Laboratories Signs Distribution Agreement with FB Reagents to Sell Deuterated Phospholipids and Detergents

Cambridge Isotope Labs (CIL) is proud to offer an assortment of deuterated phospholipids and detergents manufactured by FB Reagents, Ltd. These compounds are being used to solubilize isotopically labeled membrane proteins for high-field nuclear magnetic resonance (NMR) spectroscopy, and to study membrane structure by small-angle neutron scattering (SANS). FBR’s products expand significantly CIL’s current offering of deuterated lipids and detergents.

June 4, 2020 – CIL Aids COVID-19-Related Research at MIT with 13C6 Glucose

CIL is aiding COVID-19-related research currently being conducted in the laboratory of Dr. Mei Hong, a professor of chemistry at MIT (Cambridge, MA.). The Hong laboratory develops and applies magic-angle-spinning solid-state NMR spectroscopy to elucidate the structure and dynamics of biological macromolecules. One current research focus of the Hong group is to determine the structure and binding mechanism of a severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) membrane protein.

May 18, 2020 – Cambridge Isotope Laboratories Partners with Alsachim in the Fight Against COVID-19

Through a commercial partnership with Alsachim, Cambridge Isotope Labs (CIL) is proud to now offer an assortment of unlabeled and stable isotope-labeled antiviral drug standards and their metabolites to assist in COVID-19 research and therapy development.

March 17, 2020 – CIL's Response to Coronavirus (COVID-19)

As we continue to monitor and respond to the changing business dynamics created by the Coronavirus (COVID-19), the entire CIL team extends our best wishes to you, your employees and families for good health and peace of mind during a difficult time.

CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.